Previous 10 | Next 10 |
VistaGen Therapeutics (NASDAQ: VTGN ), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders,...
At the conclusion of the 2021 Russell Indexes annual reconstitution, biopharmaceutical company VistaGen Therapeutics (VTGN) will join the Russell 2000 Index, effective June 28 after the U.S. market opens. VistaGen is developing new generation medicines for multiple ((CNS)) diseases and ...
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxi...
VistaGen Therapeutics (VTGN) announces the initiation of its PALISADE Phase 3 clinical program with a late-stage, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of PH94B for the acute treatment of adults with Social Anxiety Disorder ((SAD)).PH...
PALISADE Phase 3 Program focused on acute treatment of anxiety in adults with Social Anxiety Disorder FDA Fast Track designation granted Topline results anticipated in mid-2022 SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics Inc....
Penny Stocks To Buy According To Top Wall Street Firms What do you look for when it comes to finding penny stocks to buy? Are you hunting for momentum? Should corporate filings be part of your research? Will news headlines play a role in your decision-making? What about industry sentime...
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will present at two invest...
Virgin Galactic Holdings (SPCE) +21% after test flight scheduled for May 22VistaGen Therapeutics (VTGN) +15% after Baird calls stock 'significantly undervalued'.Allogene Therapeutics (ALLO) +13% on positive early-stage data for CAR T candidates in blood cancer.PDS Biotechnology...
SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervou...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back once again, investors, and let’s get ready for a busy day of trading! We’re kicking off the day with a look at the biggest pre-market stock movers for Thursday below. Source: oneinchpunch/Shut...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen Therapeutics (NASDAQ: VTGN ), a clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, has received multiple new patent...
Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global in...
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to pr...